ARIA Registry Study

Registry study on risk factors for cerebral amyloid angiopathy and amyloid-related imaging abnormalities (ARIA)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1040250118

Enrollment

430

Registered

2025-10-22

Start date

2025-10-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral amyloid angiopathy or Alzheimers disease Alzheimer's diseas

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Individuals diagnosed with cerebral amyloid angiopathy or Alzheimer's disease 2 Individuals meeting any of the following selection criteria for each cohort group [Cohort 1: Spontaneous ARIA Group] -CAA-ri group: Individuals diagnosed with CAA-ri -Control group: Individuals diagnosed with CAA and without ARIA at the time of registration However, Cohort 1 participants must not receive anti-A-beta antibody drug administration during the study period. [Cohort 2: Anti-A-beta Antibody Drug-Related ARIA Cohort] -ARIA group: Individuals currently receiving or with a history of anti-A-beta antibody drug treatment based on guidelines for optimal use, who developed ARIA -Control group: Individuals scheduled to receive or currently receiving anti-A-beta antibody therapy based on optimal use guidelines, without ARIA at registration 3 Individuals for whom written informed consent was obtained from the subject or legal representative regarding study participation

Exclusion criteria

Exclusion criteria: Individuals deemed ineligible for inclusion in the study by the principal investigator or co-investigator

Design outcomes

Primary

Measure	Time frame
Not set	—

Contacts

Public ContactHidehiro Ishikawa

Mie University

hidehiro-i@med.mie-u.ac.jp+81-59-231-5107

Outcome results